# FDA 483 - New York Blood Center Enterprises - April 23, 2026

Source: https://www.keypedia.com/records/483/new-york-blood-center-enterprises/557f60b9-3898-4a01-855c-b3e4b2afa637

> FDA 483 for New York Blood Center Enterprises on April 23, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: New York Blood Center Enterprises
- Inspection Date: 2026-04-23
- Product Type: biologics
- Office Name: New York District Office
- Summary: An FDA inspection of New York Blood Center Enterprises in Ronkonkoma, NY, a donor center, revealed that written standard operating procedures for the collection of blood and blood components were not consistently followed. Specifically, issues were noted with the initiation of apheresis collection after sampling and the proper leveling of collection instruments. These findings indicate procedural deviations in critical blood collection processes.

## Related Documents

- [483 - 2023-12-22](https://www.keypedia.com/records/483/new-york-blood-center-enterprises/28217af4-b0f5-4f6c-8ba3-6e1b20a287ad)

## Related Officers

- [Investigator](https://www.keypedia.com/people/irina-gaberman/c863b2de-4c64-40d2-a390-289d293e5a8f)

Company: https://www.keypedia.com/companies/new-york-blood-center-enterprises/9f2a4f56-c3b2-4ee4-95a2-a77827302570

Office: https://www.keypedia.com/offices/new-york-district-office/9fa3d265-16ca-438d-8a6e-b47f60dc260d